Head and Neck Oncology Journal Club

The METRO PLUS Trial: Metronomic Chemotherapy Added to Paclitaxel-Carboplatin in Advanced HNSCC 04.07.2026 6:50 ↓

Can a $180-a-year regimen close the access gap in advanced head and neck cancer? In this episode we cover METRO PLUS (Kapoor et al., JCO Global Oncology 2026), a single-center, open-label, phase III trial from Varanasi testing whether adding triple oral metronomic chemotherapy — erlotinib, celecoxib, and weekly methotrexate — to paclitaxel-carboplatin improves survival in platinum-sensitive, unres...

Thyroglossal Duct Cyst Excision: Sistrunk Procedure 28.06.2026 4:19 ↓

Audio companion to our surgical video on the Sistrunk procedure for thyroglossal duct cyst. Embryology, why simple excision recurs, and a concise step-by-step of the operation — incision, subplatysmal flaps, strap separation, central hyoid skeletonisation and resection, en bloc specimen delivery, and layered closure. Watch the dissection: https://www.youtube.com/watch?v=cki1r1fIAw8

Neoadjuvant Chemoimmunotherapy vs Immunotherapy Alone in HNSCC 28.06.2026 6:49 ↓

A 23-study, 751-patient meta-analysis asks a practical question: when you give neoadjuvant immunotherapy before surgery in resectable head and neck cancer, does adding chemotherapy actually help? Baratz and colleagues (Mayo Clinic, JAMA Otolaryngology–Head & Neck Surgery , March 2026) pooled the prospective phase 1 and 2 data across three regimens — chemoimmunotherapy, single-agent immunothera...